4th Quarter - Report — GENENTECH, INC for GENENTECH INC (2008)

Firm

GENENTECH, INC

Client

GENENTECH INC

Income

—

Expenses

$775,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 1424, Emergency Economic Stabilization Act of 2008 S. 2029, Physician Payments sunshine Act of 2007 Comparative Effectiveness

Lobbyist	Covered position, as disclosed
DAVID B BURT	—
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: S. 2029 (110th), H.R. 1424 (110th)

Taxation/Internal Revenue Code TAX

Tax legislation/R&D tax credit

Lobbyist	Covered position, as disclosed
DAVID B BURT	—
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Comparative Effectiveness

Lobbyist	Covered position, as disclosed
DAVID B BURT	—
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Pharmacy PHA

H.R. 1038, Acces to Life-Saving Medicine Act, follow-on biologics H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H.R. 5629, Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions

Lobbyist	Covered position, as disclosed
DAVID B BURT	—
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 1956 (110th), S. 1695 (110th), S. 2029 (110th), S. 596 (110th), H.R. 1038 (110th), H.R. 5839 (110th), H.R. 5629 (110th)

Medical/Disease Research/Clinical Labs MED

LHHS Appropriations (CMS and comparative effectiveness related matters) S.3408 Comparative Effectiveness Research Act of 2008

Lobbyist	Covered position, as disclosed
DAVID B BURT	—
WALTER MOORE	—
PETER JOSEPH MULLER	—
HEIDI L WAGNER	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP)

Bills named: S. 3408 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.